Overview

Safety Study of Bile Acid to Treat Hypercholesteremia

Status:
Unknown status
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
Preclinical data support the hypothesis that the administration of AHRO-001 reduces LDL cholesterol levels, improves HDL function, and finally, decreases atheromatous plaque burden.
Phase:
Phase 1
Details
Lead Sponsor:
AtheroNova Inc.